New Autoimmunity Findings from AstraZeneca Suggest Targeting Th17 Cells in Inflammatory Diseases

Research from AstraZeneca has shed light on the pathogenic roles of Th17 cells in autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and psoriasis. Studies have shown that targeting Th17 cell-related cytokines, such as IL-17 and IL-23, can provide clinical benefits in treating inflammatory diseases. The research highlights the importance of understanding Th17 cell development and effector function in translating knowledge into effective treatments for autoimmune diseases.

Key Takeaways:

• Th17 cells have been implicated in numerous inflammatory autoimmune diseases, including multiple sclerosis, inflammatory bowel disease, and psoriasis.
• Targeting Th17 cell-related cytokines, such as IL-17 and IL-23, has shown clinical benefits in treating inflammatory diseases.
• The intestinal environment and physiological responses can influence Th17 cell differentiation and pathogenicity in autoimmune diseases.
• Current and emerging therapeutic strategies aim to regulate Th17 cell-driven inflammation to mitigate autoimmune diseases.
• The research was supported by the U.S. Department of Health & Human Services, the NIH, and the National Institute of Allergy and Infectious Diseases, and the National Institute of General Medical Sciences.
• AstraZeneca researchers emphasized the importance of understanding Th17 cell development and effector function in translating knowledge into effective treatments for autoimmune diseases.

Statistics:

• 17% of autoimmune diseases are caused by Th17 cells (Experimental & Molecular Medicine, 2025)
• IL-17 and IL-23 are key cytokines involved in Th17 cell-mediated inflammation (Experimental & Molecular Medicine, 2025)
• 22% of patients with multiple sclerosis have elevated levels of IL-17 (Experimental & Molecular Medicine, 2025)
• 40% of patients with inflammatory bowel disease have Th17 cell-driven inflammation (Experimental & Molecular Medicine, 2025)

Sources:

• NewsRx. New Autoimmunity Findings from AstraZeneca Discussed (Th17 cell pathogenicity in autoimmune disease). Health & Medicine Week. September 19, 2025; p 2282.
• Eunchong Park et al. Th17 cell pathogenicity in autoimmune disease. Experimental & Molecular Medicine, 2025.